Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation

Clin Transplant. 2010 Jul:24 Suppl 22:16-21. doi: 10.1111/j.1399-0012.2010.01278.x.

Abstract

As immunosuppressive therapy has advanced, we have markedly improved the outcome of ABO blood group incompatible living donor kidney transplantation. Consequently, graft survival at early phase after ABO-incompatible transplantation has been favorable than ABO-compatible transplantation in Japan. But in these days, it has been assumed that transplant glomerulopathy within one yr after ABO-incompatible kidney transplantation might be significantly precipitated. That may be because of chronic, active antibody-mediated rejection (AMR). We performed kidney graft biopsies at the early phase within 90 d after living donor kidney transplantation that involved the episode and protocol biopsies and studied findings of graft biopsy specimens when compared with ABO incompatible and compatible involving non-identical and identical transplantations. In ABO-incompatible transplant cases, the ratio occurring glomerulitis, especially severe injury of g 2-3, was significantly higher than that of identical and non-identical transplant cases (p < 0.01). There was no significant difference in t score, i score, ptc score and v score between three transplant groups. The cases occurring AMR were concordant with the cases recognized with severe glomerulitis. AMR was difficult to be diagnosed by C4d analysis in ABO-incompatible transplant cases. Glomerular injury score, g score, may be considered as more significant and the injury should be cured thoroughly.

Publication types

  • Comparative Study

MeSH terms

  • ABO Blood-Group System / immunology*
  • Adult
  • Biopsy
  • Blood Group Incompatibility*
  • Female
  • Graft Rejection / immunology*
  • Graft Survival / immunology*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology*
  • Living Donors*
  • Male
  • Middle Aged

Substances

  • ABO Blood-Group System
  • Immunosuppressive Agents